Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
Relapse during treatment (4 to 12 months) · SSNS in children
Levamisole may leads to lower relapse during treatment (4 to 12 months) compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Levamisole may leads to lower relapse at 6 to 12 months compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
1 finding from 1 review
Adverse effects: leucopenia · SSNS in children
Levamisole showed no clear difference in adverse effects: leucopenia compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Adverse effects: ANCA positive/arthritis · SSNS in children
Levamisole showed no clear difference in adverse effects: ANCA positive/arthritis compared with steroids or placebo or both, or no treatment (low certainty).
1 finding from 1 review
Clinical relapse · SSNS in children
Alkylating agents probably leads to lower relapse at 6 to 12 months compared with steroids, placebo or both (moderate certainty).
2 findings from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CPA: leucopenia · SSNS in children
Alkylating agents led to higher CPA: leucopenia compared with steroids, placebo or both; GRADE not reported.
1 finding from 1 review
RR 10.63 [1.45, 78.05]
Studies not reported
GRADE not reported
Chlorambucil: leucopenia · SSNS in children
Alkylating agents showed no clear difference in chlorambucil: leucopenia compared with steroids, placebo or both; GRADE not reported.
1 finding from 1 review
RR 2.5 [0.11, 54.87]
Studies not reported
GRADE not reported
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Remission · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT compared with corticosteroids (very low certainty).
1 finding from 1 review
Remission rate ‐ ITT adult studies · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT adult studies compared with corticosteroids (very low certainty).
1 finding from 1 review
Remission rate ‐ ITT pediatric studies · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT pediatric studies compared with corticosteroids (very low certainty).
1 finding from 1 review